Bayer

Contact Us

Congress Library

American College of Cardiology 2026

Posters

Agarwal mechanisms of cardiovascular benefit Agarwal mechanisms of cardiovascular benefit

Carolyn Lam

Assessing Factors Associated with Sodium-Glucose Cotransporter 2 Inhibitors Initiation in a Contemporaneous Cohort of Newly Diagnosed HF Patients from the US

Click to access
Biomarker, Functional Status Biomarker, Functional Status

Henri Lu

Biomarker, Functional Status, and Quality of Life Trajectories Before Modes of Death in Heart Failure 

Click to access
Chimura_EMPEROR-Preserved Risk Score Chimura_EMPEROR-Preserved Risk Score

Misato Chimura

Performance of EMPEROR Preserved Risk Model in FINEARTS-HF

Click to access
Mingming Yang Mingming Yang

Mingming Yang

Serum Creatine Kinase Concentration and Clinical Outcomes in Patients with HFmrEF/HFpEF

Click to access
ACC2026_Butt_ FINEARTS-HF CHD.pdf ACC2026_Butt_ FINEARTS-HF CHD.pdf

Jawad Butt

Finerenone, Coronary Heart Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial

Click to access
ee ee

Alireza Manafi

Finerenone, Pulse Pressure, and Cardiovascular Outcomes in Heart Failure with Mild Reduced and Preserved Ejection Fraction

Click to access
ACC2026_Siqueira_FIDELITY Risk Factor Control ACC2026_Siqueira_FIDELITY Risk Factor Control

Sara Siqueira

Risk Factor Control, Cardiovascular Outcomes, and Finerenone in Type 2 Diabetes and Chronic Kidney Disease: FIDELIO-DKD and FIGARO-DKD Trials

Click to access
ACC2026_Schneider_Sleep Apnea_FINEARTS-HF. ACC2026_Schneider_Sleep Apnea_FINEARTS-HF.

Sophia R. Schneider

Sleep Apnea in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial

Click to access
ACC20206_Hamatani_KCCQ12 vs KCCQ23 ACC20206_Hamatani_KCCQ12 vs KCCQ23

Yasuhiro Hamatani

Validation of the KCCQ-12 against KCCQ-23 across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure Independent Analysis

Click to access

Follow Us

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

Copyright © 2026 Bayer

Bayer and the Bayer Cross are registered trademarks of Bayer.

sitemap